Pre season talk about influenza vaccines: correct cognition without hesitation

2023-09-12

Luwang, September 11th (Reporter Guan Xiaohui, Correspondent Li Chengxiu, Ma Jin) Influenza is an acute respiratory infectious disease caused by the influenza virus that poses a threat to human health. It is seasonal (commonly known as the "flu season") and can cause serious complications such as pneumonia, encephalitis, and even death in infants, young children, and the elderly. Therefore, outbreaks of COVID-19 are prone to occur in schools, kindergartens, and elderly care institutions. Although there was a nationwide outbreak of H1N1 influenza A from February to April this year, according to perennial epidemiological data in China, the southern and northern regions generally have a high incidence in winter and spring (November to February of the following year), and the areas south of the Yangtze River can also have a high incidence in summer. Therefore, we are currently in the pre flu season, which is the best time to receive influenza vaccines, especially for infants, young children, primary and secondary school students, the elderly, medical personnel, and entry-exit port staff. However, due to cognitive differences, some parents and vaccination populations have varying degrees of hesitation in vaccination, mostly suspecting the effective protection of the vaccine, followed by anxiety about vaccination safety. For this, let's talk about topics related to influenza vaccines together.

The 2nd one in China! Kexing EV71-CA16 Bivalent HFMD Vaccine Approved for Clinical Use

2023-07-19

The 2nd one in China! Kexing EV71-CA16 Bivalent HFMD Vaccine Approved for Clinical Use

Cell: Two birds with one stone! A Cancer Vaccine Breaks Barriers to CAR-T Therapy, Promising "Complete Clearance" of Solid Tumours

2023-07-11

The most groundbreaking anti-cancer strategy of chimeric antigen receptor T-cell (CAR-T) therapy is to modify self-sourced T-cells so that they can more precisely target cancer cells. Globally, several CAR-T therapies have been approved, giving doctors a new weapon in the face of malignant tumours, especially haematological tumours, that they were previously unable to do anything about.

Domestic clinical trial approved for bivalent mRNA vaccine against Emmy vaccine

2023-07-03

Aimé Vaccines announced on the Hong Kong Stock Exchange on 29 June that the company's bivalent mRNA New Crown vaccine for the Delta and Omicron BA.5 variants under development has been approved for clinical trials by the State Drug Administration. Research data has shown that this vaccine shows high level of neutralising antibodies against the XBB mutant strain.

Domestic mRNA rabies vaccine first clinical acceptance, the new crown after the vaccine R & D targeting these areas

2023-06-13

On June 10, information on the official website of the Centre for Drug Evaluation (CDE) of the State Drug Administration showed that the application for clinical trial of human rabies mRNA vaccine of Livanda Biologicals, a subsidiary of domestic private vaccine maker Aimee Vaccines, has been accepted. This signifies that the first rabies mRNA vaccine declared for clinical use in China is expected to enter the clinic soon.

World's First! Visco Bio/Kawasaki University's vaccine against XBB and other new coronaviruses approved for emergency use by the state

2023-06-13

On 8 June 2023, the recombinant trivalent neocoronavirus (XBB.1.5+BA.5+Delta variant) trimeric protein vaccine (Sf9 cells) developed by Wisker Biotech/Chuan Da Huaxi - Wikxin® 3-valent XBB vaccine was included in the emergency use with the approval of the relevant state departments, which is the world's first neocoronavirus vaccine approved for emergency use against the mutant strains of XBB and other mutants, marking that China's This is the first new crown vaccine approved for emergency use in the world against XBB and other mutant strains, signifying that China's research and development of new crown vaccines has been at the forefront of the world.